Icelandic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Remifemin Preventing the Climacteric Symptoms in Breast Cancer

Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Krækjan er vistuð á klemmuspjaldið
StaðaLokið
Styrktaraðilar
Zhejiang Cancer Hospital

Lykilorð

Útdráttur

LHRH-a is an important hormone treatment in breast cancer especially in high-risk hormone receptor-positive patients or hormone receptor-negative but needing ovarian function protecting. The climacteric symptoms caused by LHRH-a are often and prominent, which is a common clinical problem.

Lýsing

Ovarian function suppression (OFS) or protection has been studied widely in breast cancer. As an common drug in clinic, LHRH-a is an important method for OFS in breast cancer especially in high-risk hormone receptor-positive patients or hormone receptor-negative but needing ovarian function protecting. The climacteric symptoms caused by LHRH-a are often and prominent, which is a common clinical problem. Remifemin (cimicifuga racemosa / black cohosh) is effective in climacteric symptoms as a hormone replacement treatment, some research concluded that it is also safe in breast cancer patients who are postmenopausal or taking tamoxifen suffering from climacteric symptoms. While in China, more than 2/3 breast cancer patients are pre/peri-menopause, and some part of them should take OFS as an hormone treatment. OFS can cause sever climacteric symptoms in a short time. The investigators aim to estimate the effect and safety of Remifemin in climacteric symptoms caused by OFS in breast cancer.

Dagsetningar

Síðast staðfest: 06/30/2018
Fyrst lagt fram: 10/14/2017
Áætluð skráning lögð fram: 11/06/2017
Fyrst sent: 11/12/2017
Síðasta uppfærsla lögð fram: 07/03/2018
Síðasta uppfærsla sett upp: 07/05/2018
Raunverulegur upphafsdagur náms: 01/03/2017
Áætlaður aðallokunardagur: 11/26/2017
Áætlaður dagsetningu rannsóknar: 01/29/2018

Ástand eða sjúkdómur

Effect of Drugs
Safety Issues

Íhlutun / meðferð

Drug: Remifemin intervention

Stig

Stig 2

Armhópar

ArmurÍhlutun / meðferð
Experimental: Remifemin intervention
Using Remifemin during LHRH-a treatment in breast cancer
Drug: Remifemin intervention
Remifemin 0.2g po bid*12 weeks at the beginning of the LHRH-a treatment
No Intervention: Control
No intervention during LHRH-a treatment in breast cancer

Hæfniskröfur

Aldur hæfur til náms 18 Years Til 18 Years
Kyn sem eru hæf til námsFemale
Tekur við heilbrigðum sjálfboðaliðum
Viðmið

Inclusion Criteria:

1. provision of informed consent

2. clinical stage I~IIIC

3. histologically proven invasive breast cancer

4. women defined as premenopausal according to NCCN guideline

5. plan to accept the LHRH-a as endocrine treatment or ovarian function protection

Exclusion Criteria:

1. clinical evidence of metastatic disease

2. bilateral oophorectomy

3. patients who, for whatever reason (e.g., confusion, infirmity, alcoholism), are unlikely to comply with trial requirements

4. patients who accepted anti-cancer treatment before

5. previous hormonal therapy as adjuvant treatment for non-cancer disease

6. patients unwilling to stop taking any drug known to affect sex hormonal status, or in whom it would be inappropriate to stop previous history of invasive malignancy within the last 5 years, other than squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix, adequately cone biopsied

7. treatment with a non-approved or experimental drug during 1 month before entry into the study

8. history of bleeding diathesis (i.e., Disseminated intravascular coagulation, clotting factor deficiency), or long term anticoagulant therapy (other than antiplatelet therapy and low dose warfarin)

9. leukopenia and/or thrombocytopenia

10. history of ocular fundus diseases

11. history of thromboembolic diseases

12. history of osteoporotic fractures

Útkoma

Aðal niðurstöður ráðstafanir

1. Kupperman Item (KMI) [3 months after treatment]

Scoring according to Kupperman item scale (Total: 0-48, the score higher the symptoms are severer) which includes of hot flash, sweat, insomnia, anxious, depressed, vertigo, fatigue, arthralgia, headache, palpitate (each item has a weighting coefficient according to four grade scores: no symptom *0, sometimes *1, always *2, influent life *3).

Aðgerðir vegna aukaatriða

1. Disease free survival [2 years]

Disease free survival rate in 2 years

Skráðu þig á
facebook síðu okkar

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum

  • Virkar á 55 tungumálum
  • Jurtalækningar studdir af vísindum
  • Jurtaviðurkenning eftir ímynd
  • Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
  • Lestu vísindarit sem tengjast leit þinni
  • Leitaðu að lækningajurtum eftir áhrifum þeirra
  • Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum

Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum

Google Play badgeApp Store badge